Previous close | 3.0900 |
Open | 3.0300 |
Bid | 2.7500 x 1000 |
Ask | 3.0200 x 2200 |
Day's range | 2.8600 - 3.1375 |
52-week range | 0.9550 - 3.3800 |
Volume | |
Avg. volume | 1,467,268 |
Market cap | 69.031M |
Beta (5Y monthly) | 1.19 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.8860 |
Earnings date | 13 Mar 2023 - 17 Mar 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.29 |
SOUTH SAN FRANCISCO, Calif., January 09, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for advancing tildacerfont in classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).
SOUTH SAN FRANCISCO, Calif. & TOKYO, January 05, 2023--Spruce Biosciences & Kaken Pharmaceutical Announce Strategic Partnership & Exclusive Licensing Agreement to Develop Tildacerfont for CAH in Japan
SAN FRANCISCO, November 10, 2022--Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates